US 505(b)(2) Regulatory Pathway and Strategies
US 505(b)(2) Regulatory Pathway and Strategies
US 505(b)(2) Regulatory Pathway and Strategies
- No tags were found...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Case Study: Valacyclovir• Oral tablet for treatment of herpes– Pro-drug of acyclovir– Pro-drug in systemic circulation for about 30 min– Hepatic esterases convert pro-drug to acyclovir– Similar plasma metabolic profile to acyclovir afterconversion